FDA Reviews Generic Tirzepatide Applications Amid Ongoing Patent Protections

Federal regulators have initiated a review of applications for generic versions of the tirzepatide-based medications Mounjaro and Zepbound. The manufacturer, Sandoz, seeks approval for these injectable treatments, which are currently indicated for type 2 diabetes, obesity, and sleep apnea.

While the regulatory review process typically spans ten months, the commercial viability of these generics in the United States remains constrained by existing patent protections. Current intellectual property rights for the brand-name medications are held by Eli Lilly and are scheduled to remain in effect until 2036.

Market entry for these generics prior to 2036 would require either a successful legal challenge to the existing patents or specific regulatory authorization. The introduction of lower-cost alternatives is projected to increase market competition and expand patient access, provided that legal and patent barriers are resolved.